SUNNYVALE, Calif., Nov. 1, 2013 /PRNewswire/ -- ARRAYit
Corporation (OTCQB: ARYC) reports that it has received a
$72,297 purchase order from ChemBio,
the company's high-powered distributor in Moscow, Russia. ChemBio, which is Russia's premiere distributor of life sciences
products and services, represents ARRAYit, Corning, Molecular
Devices, Nalgene and other leading corporations, providing Russian
customers with market information, technical assistance,
installation, product support and training.
ChemBio purchased the patented and proprietary ARRAYit
Microarray Platform including a SpotBot® 3 Protein Edition Desktop
Personal Microarrayer and 126 additional instruments, tools, kits,
reagents and consumables for advanced microarray research and
development.
ARRAYit currently has a worldwide installed customer base of
over 390 SpotBot® instruments, representing $8 million in aggregate revenue to the company.
ARYC expects to report the sales and earnings from the ChemBio
transaction in the current quarter.
About ARRAYit
Corporation
ARRAYit Corporation is a Sunnyvale,
California-based company leading and empowering the genetic,
research, pharmaceutical, and diagnostic communities through the
discovery, development, and manufacture of proprietary life science
technologies and consumables for disease prevention, treatment and
cure. The company's innovative products and services help
scientists and clinicians explore the human genome as well as the
genomes of plants and animals. ARRAYit's products are used by
nearly every major research center in the world.
About Liston Street
Pulse
Liston Street Pulse is a leading
provider of financial research. The company has significant
expertise in U.S. listed small cap and micro-cap stocks. Subscribe
here to read more about ARYC, including CEO interviews.
Safe Harbor Statement
Except for historical information contained herein,
statements made in this release that constitute forward-looking
statements are based on currently available information, involve
certain risks and uncertainties and the Company assumes no
responsibility to update any such forward-looking statement. The
following factors, among others, may cause actual results to differ
materially from the results suggested in the forward-looking
statements. Risks that may result from changes in the Company's
business operations; our ability to keep pace with technological
advances; significant competition in the biomedical business; our
relationships with key suppliers and customers; quality and
consumer acceptance of newly introduced products; market
volatility; non-availability of product; excess inventory; price
and product competition; new product introductions, the outcome of
our legal disputes; the possibility that the review of our prior
filings by the SEC may result in changes to our financial
statements; and the possibility that stockholders or regulatory
authorities may initiate proceedings against ARRAYit and/or our
officers and directors as a result of any restatements. Risk
factors associated with our business, including some of the facts
set forth herein, are detailed in the Company's Form 10-K for the
fiscal year ended December 31, 2012
and Form 10-Q for the fiscal first quarter ended March 31, 2013, Form 10-Q for the fiscal second
quarter ended June 30,
2013.
SOURCE ARRAYit Corporation